Medivation-Astellas EAP for enzalutamide gets FDA clearance

The US Food and Drug Administration (FDA) has allowed Medivation and Astellas to proceed with an Expanded Access Program (EAP) for the investigational therapy enzalutamide (formerly MDV3100) under a t…
Read the full story: PBR - Clinical Trials News